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GABAA and excitatory amino acid receptors in dorsomedial
hypothalamus and heart rate in rats
Robert P. Soltis and Joseph A. DiMicco
Department of Pharmacology and Toxicology, Indiana University
School gf Medicine, Indianapolis, Indiana 46202

We have previously shown that microinjection of drugs that interefere with the function of the
inhibitory neurotransmitter γ-aminobutyric acid (GABA) into the hypothalamus produces cardiorespiratory
and behavioral changes resembling those seen in emotional stress. The purpose of this study was to
determine whether excitatory amino acids (EAAs) can produce a cardiovascular response similar to that
caused by the GABAA receptor antagonist bicuculline methiodide (BMI) when microinjected at the same
hypothalamic site in urethan-anesthetized rats and to clarify the precise locus of action of these agents. Nmethyl-D-aspartic acid (NMDA, 0.68-6.8 pmol/50 nl) and kainic acid (KA, 0.47-4.7 pmol/50 nl) produced
dose-related increases in heart rate and blood pressure when injected at sites in the dorsomedial
hypothalamus reactive to BMI (20 pmol/50 nl). Higher doses of NMDA (68 pmol), however, failed to elicit
consistent increases in heart rate and blood pressure when injected at these same sites. The effects of NMDA
were selectively blocked by the NMDA receptor antagonist 2-amino-5 phosphonopentanoic acid, whereas
the effects of KA were selectively blocked by the non NMDA EAA receptor antagonist 6-cyano-7nitroquinoxaline-2,3dione. These results demonstrate that 1) blockade of inhibitory amino acid receptors
or stimulation of EAA receptors in the dorsomedial nucleus of the hypothalamus produces tachycardic and
pressor responsesin urethan-anesthetized rats and 2) use of high doses of EAAs may be an unreliable
method of evoking local neuronal excitation in certain regions of the central nervous system.
_____________________________________________________________________________________

Historically, the hypothalamus has been implicated in playing an important role in the autonomic
and behavioral responses to emotional stress. Electrical stimulation of the hypothalamus evokes a
characteristic pattern of changes that includes increases in blood pressure and heart rate as well as
behavioral effects (17,34). However, the utility of electrical stimulation studies in mapping the central
nervous system is questionable because electrical stimulation excites all local neural elements including
fibers of passage. Thus interpretation of these studies is uncertain because the observed responses may
result from activation of local neurons or axons projecting through the area of stimulation (21). A more
recently developed technique to evoke local excitation of neurons involves the use of excitatory amino acids
(EAAs). This approach, now widely employed, is thought to be advantageous over electrical stimulation

because EAAs are capable of exciting most if not all neurons in the mammalian central nervous system
without affecting fibers of passage (11).

Recent studies have tested the hypothesis that, at hypothalamic sites at which electrical stimulation
elicits increases in blood pressure and heart rate, chemical stimulation will produce similar responses.
Microinjection of molar concentrations of either glutamate or dl-homocysteic acid (DLH) at various
hypothalamic sites failed to produce consistent increases in both heart rate and blood pressure (4, 10, 12,
27). Therefore, these investigators concluded that excitation of hypothalamic neurons does not result in
tachycardia and hypertension and that some of the changes seen with electrical stimulation were the result
of activating fibers of passage. Yet, other microinjection studies have demonstrated that prostaglandin E2
(9), α-melanocyte-stimulating hormone (8), or drugs that interfere with the function of the inhibitory
neurotransmitter γ-aminobutyric acid (GABA) (6, 7, 32, 33) can act within the hypothalamus to produce
changes in cardiovascular function similar to those seen with electrical stimulation, i.e., tachycardia and
hypertension. Furthermore, removal of the functional activity of neurons at these same sites by either
microinjecting the GABAA receptor agonist muscimol (16) or electrolytic lesioning (26) prevents the
tachycardia and hypertension associated with stress. These latter studies therefore suggest that activation
of neurons in the hypothalamus does, indeed, result in increases in heart rate and blood pressure and that
these same neurons may play an important role in mediating the cardiovascular responses to experimental
stress.

The conflicting results of studies involving intrahypothalamic microinjection of EAAs and other
drugs such as the GABA antagonists might be explained in at least two ways. First, glutamate and DLH
may have been injected at hypothalamic sites other than those at which GABAergic drugs act to produce
cardiovascular effects. Because previous studies involving intrahypothalamic injection of GABA
antagonists usually employed relatively large volumes (0.25-l μl), the exact site of action of these agents
may be in question. This uncertainty is further compounded by an apparent error, recently highlighted by
Spencer and colleagues (27), regarding the delineation of the borders of the posterior hypothalamic nucleus
and the dorsomedial nucleus of the hypothalamus in the atlas of Pellegrino et al. (20). Second, the injected
doses of these EAAs may have been so high as to elicit depression rather than excitation of local neural
activity, a phenomenon that has been shown to occur after injection of molar concentrations of EAAs in
other areas of the central nervous system (15). To test these possibilities, we microinjected picomolar doses
of the relatively selective EAA receptor agonists N-methyl-D-aspartate (NMDA) and kainic acid (KA) in
volumes of 50 nl (μm concentrations) at hypothalamic sites shown to be reactive to the GABAA receptor
antagonist bicuculline methiodide (BMI) in urethan-anesthetized rats. In addition, the EAA receptor

antagonists 2-amino-5 phosphonopentanoic acid (AP5), thought to be selective for the NMDA subtype of
EAA receptor (5), and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an agent exhibiting dose-related
selectivity for non-NMDA EAA receptors (31), were employed to determine the role of specific EAA
receptor subtypes in generating the effects of each agonist.

METHODS

Male Sprague-Dawley rats (250-350 g, Taconic Farms) were anesthetized with urethan (1.35 g/kg
ip). The left femoral artery and vein were cannulated with PE-50 tubing filled with heparinized saline. The
arterial line was connected to a pressure transducer for the direct measurement of arterial pressure with the
pulse pressure signal triggering a cardiotachometer for the measurement of heart rate. Arterial pressure and
heart rate were continuously recorded on a Beckman 511A strip chart recorder while respiratory rate was
visually monitored and recorded at appropriate times. Rectal temperature was monitored and maintained at
37 ± 0.5˚C.

Microinjections were made using glass micropipettes. Glass capillary tubing was pulled, broken
back, and then bevelled to a smooth tip with an outer diameter of 50-100 μm. The micropipette was then
attached to a length of PE-10 tubing, and the system was filled with mineral oil and water to create an oilwater interface visible with low-power magnification. The tubing was then connected to a water-filled 10μ1 Hamilton syringe mounted in a manual micrometer drive. The micropipette was loaded by placing the
oil-filled tip in a drug solution and then slowly pulling back on the syringe plunger. The drug solution was
delivered by slowly advancing the plunger with the manual micrometer drive. The distance the interface
traveled, as viewed through a stereoscope with an ocular micrometer scale, was directly proportional to the
volume delivered. Calibration studies verified the accuracy and reproducibility of this system for the
delivery of our standard microinjection volume of 50 nl. All microinjections were unilateral (right side) and
consisted of a total volume of 50 nl infused over 15-20 s. The micropipette remained in place for 1 min
after ending the infusion.

Hypothalamic sites where microinjection of the GABAA receptor antagonist BMI elicited shortlatency tachycardia were determined as in our previous studies (6, 7, 23-25, 33). The upper incisor bar was
adjusted to 5.0 mm above the interaural plane. With bregma serving as the reference point, the micropipette
was lowered to the target coordinates at a 10˚ angle with respect to the sagittal plane to avoid damaging the
midsagittal sinus. The stereotaxic coordinates for the target were posterior 1.2, right 0.5, depth -8.7
corresponding to the posterior hypothalamic nucleus according to the atlas of Pellegrino et al. (20). In early

experiments (dose-response relationship of NMDA and KA), proper placement of the micropipette was
verified by injecting 20 pmol BMI, and only those sites at which BMI produced an increase in heart rate of
≥90 beats/min with an onset of ≤30 s from the beginning of the infusion were examined further. In later
experiments (using NMDA and non-NMDA EAA receptor antagonists), proper placement of the pipette
was verified by injecting either 6.8 pmol NMDA or 2.3 pmol KA; only those sites at which the EAA
produced an increase in heart rate of ≥50 beats/min with an onset of ≤30 s from the beginning of the
infusion were studied. If the change in heart rate failed to meet these criteria, the HD or RL coordinates
were altered by 0.3 mm, and the new placement was tested until an active site was located. Once an active
site was located, the experiment proceeded with typically three or four subsequent injections spaced in time
such that any effects on heart rate caused by the previous injection had dissipated before the next injection.

In early experiments, the injection site was marked with the dye 2,3,5-triphenyltetrazolium chloride
(100 ng/50 nl, Aldrich). The animal was immediately killed, and the brain was removed and frozen at ˗80°C.
Later, coronal sections (50 μm) were cut on a freezing microtome and compared with the atlas of Pellegrino
et al. (20) for verification of the injection site. In later experiments, the injection site was marked by
microinjecting 50 nl of a solution containing india ink diluted 1:l with saline. The pipette remained in place
for 10 min at which time it was slowly removed. The animal was immediately perfused with 50 ml of saline
followed by 500 ml of fixative (1.25% glutaraldehyde, 1% paraformaldehyde in 0.1 M phosphate buffer,
pH 7.4) over 30-40 min. The brain was removed and stored in the fixative for l-3 days. Coronal sections
(40 μm) were cut on a freezing microtome, mounted on gelatin-coated slides, and stained with a 1% neutral
red solution. Location of injection sites was then determined according to the atlas of Konig and Klippel
(14) and also the atlas of Pellegrino et al. (20).

Drugs used in these experiments included urethane, decamethonium bromide, BMI, NMDA, KA,
dl-2-amino-5-phosphonopentanoic acid (all purchased from Sigma Chemical, St. Louis, MO) and CNQX
(Tocris Neuramin, UK). All drugs were dissolved in 0.9% saline solution with the final pH adjusted to 6.07.5.

Results are expressed as means ± SE. The data were analyzed by linear regression, analysis of
variance, and paired t tests. The 5% limits of probability were accepted as significant.

RESULTS

Microinjection of 2-20 pmol BMI into the dorsomedial hypothalamus caused dose-related (P <
0.05, by linear regression) increases in heart rate and blood pressure (Table 1, Figs. 1 and 2). These changes
began within 5-30 s from the start of the infusion and reached a peak effect in 3-6 min. Microinjection of
NMDA (Fig. 1, B-E) or KA (Fig. 2, B-D) at hypothalamic sites reactive to BMI produced cardiovascular
changes similar to those produced by BMI. Both NMDA (0.68-6.8 pmol) and KA (0.47-4.7 pmol) produced
dose-related (P < 0.05, by linear regression) increases in heart rate and blood pressure (Table 1, Figs. 1 and
2). However, the cardiovascular response to microinjection of higher doses of NMDA was diminished or
occasionally absent (20 and 68 pmol, Fig. 1, E and F). In a series of five experiments in which injections
of 6.8 pmol NMDA produced marked increases in heart rate (+71 ± 9 beats/min) and modest elevations in
blood pressure (+9 ± 1 mmHg), injections of 68 pmol NMDA at the same site failed to elevate heart rate
(+24 ± 21 beats/min) or blood pressure (+3 ± 3 mmHg) consistently. A similar phenomenon was not
apparent with KA. However, because of the longer time for recovery and possible excitotoxicity associated
with this agent, higher doses of KA were not systematically tested. The cardiovascular effects produced by
microinjection of either 20 pmol BMI, 6.8 pmol NMDA, or 2.3 pmol KA were reproducible over four
successive injections. Injection of the saline vehicle at sites reactive to BMI and the EAAs did not produce
significant changes from baseline in heart rate or blood pressure (Table 1).

In addition to the cardiovascular effects, 20 pmol BMI, 6.8 pmol NMDA, and 4.7 pmol KA
produced marked increases in respiratory rate estimated at 40-90 breaths/min above resting baseline values.
To determine whether the changes in heart rate were secondary to the increases in respiratory rate, the
tachycardia produced by 6.8 pmol NMDA was quantitated before and after elimination of respiratory
changes by neuromuscular paralysis (decamethonium bromide, 2 mg/kg iv) and artificial respiration with
room air in three rats. The increase in heart rate before (+65 ± 8 beats/min) and after (+67 ± 15 beats/min)
paralysis was not different (P > 0.05, paired t test). Previous work has demonstrated that the
tachytachycardic response to microinjection of BMI at this hypothalamic site is also independent of changes
in respiration (6).

To determine the role of different subtypes of EAA receptors in mediating the cardiovascular
responses to microinjection of the EAA agonists, a series of experiments were undertaken using the NMDA
receptor antagonist AP5 and the purported non-NMDA EAA receptor antagonist CNQX. In these
experiments, the response to microinjection of either 6.8 pmol NMDA or 2.3 pmol KA in the presence of
AP5 or CNQX was examined once the site was shown to be responsive to the agonist alone. Doses of the
antagonists (AP5 or CNQX) that would be both selective and effective for a given EAA receptor subtype
were established. Thus AP5 (5-50 pmol) blocked, in a dose-related (P < 0.05, by linear regression) and

reversible fashion, the cardiovascular effects of NMDA without significantly affecting the response to
microinjection of KA (Fig. 3). In a parallel series of experiments, 25 pmol CNQX markedly and reversibly
attenuated the cardiovascular effects of KA without significantly affecting the response to NMDA (Fig. 4).
Larger doses of CNQX (50 and 100 pmol) effectively antagonized the response caused by either EAA (data
not shown). Microinjection of either 50 pmol AP5 or 25 pmol CNQX alone had no significant effect on
basal heart rate (maximal changes from baseline within 10 min after injection; +5 ± 3 and -5 ± 3 beats/min,
respectively; n = 3) or blood pressure (+l ± 1 and -1 ± 1 mmHg, respectively; n = 3; P > 0.05).

In the experiments described above, subsequent histology using india ink and fixed brains (see
METHODS) indicated that the sites reactive to NMDA were localized to an area bounded laterally and
dorsoventrally by the fornix and mammillothalamic tract and medially by the third ventricle (Fig. 5).
Injection of 6.8 pmol NMDA 0.5 mm lateral, dorsal, or posterior to a reactive site typically resulted in
increases in heart rate of <20 beats/min. In 3 of the 11 experiments summarized in Fig. 5, 20 pmol BMI
was microinjected at a site defined as reactive to NMDA and produced increases in heart rate >90 beats/min.
According to the atlas of Konig and Klippel (14) or Paxinos and Watson (19), the region of the greatest
reactivity to NMDA corresponded to the dorsomedial hypothalamic nucleus (Fig. 6A ).

DISCUSSION

The results of this study provide clear evidence that the EAA receptor agonists NMDA and KA produce an
increase in heart rate and blood pressure similar to that produced by the GABAA receptor antagonist BMI
when microinjected at the same site in the dorsomedial hypothalamic nucleus of anesthetized rats. BMI,
NMDA, and KA produced, in a dose-related manner, marked increases in heart rate with modest elevations
in blood pressure. In earlier studies, we demonstrated that the cardiovascular changes caused by
intrahypothalamic injection of BMI were associated with an increase in splanchnic sympathetic nerve
activity (33) and that the tachycardia could be prevented by the ,β-receptor antagonist propranolol or by
ganglionic blockade (6). These studies would, therefore, indicate that the changes in cardiovascular function
were mediated by an increase in the activity of the sympathetic nervous system. Consequently, the
coincident site of injection and the similar pattern and onset of cardiovascular changes in the present study
suggest that the EAA agonists NMDA and KA and the GABA antagonist BMI are activating the same
cardiovascular effects.

To determine whether microinjection of NMDA and KA were, indeed, mediated by specific EAA
receptor subtypes, the EAA receptor antagonists AP5 and CNQX were used. AP5 has been identified as a

competitive antagonist selective for the NMDA receptor subtype (5,31), whereas, more recently, CNQX
has been shown to be a competitive antagonist at non-NMDA EAA receptors (13, 31). However, the
selectivity of CNQX for the non-NMDA EAA receptors is uncertain because CNQX has been shown to
antagonize NMDA receptor mediated responses by blocking the glycine regulatory site associated with this
receptor complex (2, 31). Therefore, because the selectivity of any drug is a function of its dose or
concentration, we determined a dose of each antagonist that was effective and selective. In these studies,
the antagonist was delivered in the same solution as the agonist. Concomitant administration was thought
to be advantageous over an antagonist pretreatment protocol because it would 1) reduce the number of
injections each animal received in the course of an experiment and 2) possibly allow for the use of lower
and, therefore, more selective doses of the antagonists, since larger doses given as a pretreatment might be
required to maintain an effective local concentration until injection of the agonist. Coinjection of AP5
eliminated the cardiovascular response to microinjection of NDMA at a dose (50 pmol) that did not
significantly decrease the response to KA. In a parallel series of experiments, CNQX markedly attenuated
the cardiovascular response to KA at a dose (25 pmol) that did not affect the response to NMDA. Higher
doses of CNQX (50 and 100 pmol) eliminated the response to KA but also significantly blunted the response
to NMDA. Interestingly, when either AP5 or CNQX was microinjected alone at sites previously shown to
be cardioreactive to either NMDA or KA, neither antagonist produced significant changes in heart rate,
blood pressure, nor respiratory rate from baseline. This would suggest that in urethan-anesthetized rats no
EAA receptor-mediated activity of the neurons sensitive to NMDA or KA is detectable. Conversely,
microinjection of the GABAA receptor agonist muscimol at sites reactive to the antagonist BMI also failed
to produce significant reductions in heart rate or blood pressure in urethan-anesthetized rats (32). These
findings suggest that hypothalamic neurons capable of generating tachycardia and hypertension when
activated by blockade of inhibitory amino acid receptors or stimulation of EAA receptors are quiescent and,
therefore, do not contribute to the maintenance of basal heart rate or blood pressure under these
experimental conditions.

Histology from this study indicates that the area responsive to BMI and the EAAs NMDA and KA
is localized to the dorsomedial nucleus of the hypothalamus. Previously reported work from this lab (6, 7,
16, 23-25, 33) suggested that the area responsive to GABAergic drugs was localized to the posterior
hypothalamus. The reason for this apparent inconsistency resides in our reliance before this study
exclusively on the atlas of Pellegrino et al. (20) which, as noted recently by others (27), incorrectly extends
the anterior border of the posterior hypothalamic nucleus well into the tuberal hypothalamus. Consequently,
much of the region labeled as the posterior hypothalamic nucleus in Pellegrino et al. (20) actually represents
the dorsomedial nucleus of the hypothalamus according to both Paxinos and Watson (19) and Konig and

Klippel (14) (see Figs. 5 and 6). Comparison of figures from our previous studies with either of these latter
references indicates clearly that the dorsomedial nucleus corresponds to the location of virtually all
previously localized injection sites (see Fig. 5 in Ref. 6; Fig. 1 in Refs. 23-25). Therefore, the cardiovascular
effects caused by intrahypothalamic microinjection of GABAergic drugs as previously reported were
evidently mediated by neurons originating in the dorsomedial nucleus of the hypothalamus. This conclusion
is significant in light of our previous work because the dorsomedial nucleus projects to a number of central
nervous system sites involved in the control of autonomic nervous system activity (28-30) and has been
suggested to play an important integrative role in mediating limbic influences on cardiovascular function
(1).

Recently, microinjection of KA into the paraventricular nucleus was reported to result in increases
in heart rate and blood pressure similar to those seen in the present study (22). However, the high doses of
KA (140-4,700 pmol) used in those experiments presents the possibility of the drug diffusing to and acting
at other sites in the central nervous system to produce these cardiovascular effects. Although the present
study did not directly measure the extent of the diffusion of the drug from its site of injection, the relatively
low doses and small injection volumes employed and the distribution of reactive sites suggests that the
action of these drugs is likely to be within the dorsomedial nucleus.

The present study demonstrated that intrahypothalamic injection of micromolar concentrations of
EAAs can elicit both hypertension and tachycardia. Our results contrast with the work of others in which
microinjection of 0.15-1.0 M solutions of the relatively nonselective EAAs glutamate or DLH at sites in
the hypothalamus of the rat failed to elicit any significant effects on heart rate and blood pressure (4, 10) or
produced minimal increases in heart rate accompanied by a fall in blood pressure (12). The conclusion of
these previous studies, that activation of neurons in the dorsomedial hypothalamus does not result in
increases in heart rate and blood pressure, was based on the assumption that molar concentrations of EAAs
can excite virtually all neurons, an assumption that underlies the utility of EAAs as tools to elicit local
neuronal excitation (11). However, Lipski and colleagues (15) demonstrated that although lower
concentrations elicited the expected increases in local unit activity, microinjection of 0.5-l M solutions (lo150 nl) of either glutamate or DLH failed to produce long-lasting activation as would have been predicted.
Instead, neurons in the vicinity of the injection site (0-500 μm) showed, after a brief period of excitation, a
long-lasting depression of activity. In a parallel fashion, we were able to demonstrate maximal
cardiovascular effects with NMDA and KA at concentrations of 100-150 μM [and similar injection volumes
(50 vs. 10-150 nl)], whereas microinjection of NMDA at a concentration of 1.5 mM or greater at the same
sites produced variable effects on cardiovascular function. It is possible that these higher concentrations of

NMDA were 1) producing a depolarizing blockade of the target neurons as was suggested by Lipski and
colleagues (15) and McAllen and colleagues (18), 2) diffusing to other sites to elicit changes that are
opposite or inhibitory to the observed effects, or 3) activating inhibitory interneurons at the site of injection
that are not activated by low concentrations of NMDA. Regardless of the precise mechanism responsible,
the failure to demonstrate increases in heart rate and blood pressure on microinjection of EAAs into the
dorsomedial hypothalamus in previous studies was probably related to the unreliable patterns of local
excitation associated with use of molar concentrations of EAAs.

In summary, the present study presents data that are in disagreement with recent reports suggesting
that chemical activation of cell bodies in the hypothalamus cannot generate increases in heart rate and blood
pressure (4, 10, 12). The data from our study, however, provide clear evidence that blockade of GABAA
receptors or stimulation of NMDA or non-NMDA EAA receptors in the dorsomedial nucleus of the
hypothalamus produces marked tachycardia and significant increases in blood pressure in the urethananesthetized rat. Our results also suggest that the technique of evoking local excitation of neurons by the
indiscriminate injection of a single high concentration of EAAs may have serious limitations at certain sites
in the central nervous system.
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TABLE

1. Cardiovascular effe cts caused by microinjection of BMI, NMDA, KA, or saline into dorsomedial

hypothalamus in anesthetized rats
Baseline

Maximum Change

BP,
HR,
Recovery, beats/min mmHg
Hg
min
Saline

HR,
beats/min
min

BP,
mm

Time to

Max HR,

400±20

99±1

+8±3

+2±1

379±10
8.1±1.0
364±15
9.5±0.7
363±12
15±2.0

99±2

+18±2*

+4±2

3.0±0.2

98±5

+69±13*

+6±2*

4.1±0.4

50%

BMI
2 pmol
10 pmol
20 pmol

103±3

+105± 7*

+17±3*

4.5±0.6

351±19
371±16
375±15

103±2
104±4
106±3

+13±1*
+36±6*
+65±5*

-3±1
+5±2
+7±1*

0.7±0.2
0.9±0.1
1.1±0.1

1.7±0.2
2.7±0.3
3.4±0.2

380±8
381±12
384±21

88±3
104±4
103±4

+25±4*
+45±5*
+73±8*

+4±1*
+7±1*
+13±2*

1.7±0.3
2.5±0.5
:3.6±0.3

4.5±1.0
9.0±0.9
36±4.0

NMDA
0.68 pmol
2.0 pmol
6.8 pmol

KA
0.47 pmol
1.4 pmol
4.7 pmol

Values are means ± SE (n = 4 for BMI , NMDA, KA, and saline). HR, heart rate; BP, blood pressure; see text for additional
definitions for abbreviations. BMI (20 pmol) produced increases in HR and BP of 115 ± 9 beats/min and 13 ± 2 mmHg (n =
8), respectively, i n group of rats injected with either NMDA or KA.* Significant change from baseline by paired t test (P <
0.05). See text for abbreviations.

FIG. 1. Tracing of blood pressure (BP, mmHg) and heart rate (HR, beats/min) depicting effects of microinjection of bicuculline methiodide (RMI;
A ) and increasing doses of N-methyl-D-aspartic acid (NMDA; B-F) at same site in doromedial hypothalamus of a single urethan -anesthetized rat.
Microinjection of 6.8 pmol NMDA 55 min after injection of 68 pmol NMDA (F) produced increases in HR and BP of 70 beats/min and 10 mmHg,
respectively. Injections were made in 50 nl of saline and spaced 45-60 min apart. Maximum changes in BP and HR are indicated.

FIG;. 2. Tracing of blood pressure (BP, mm Hg) and heart rate (HR, beats/min) depicting effects of microinjection of bicuculline methiodide
(BMI; A ) and increasing doses of kainic acid (KA; B-D) at same site in dorsomedial hypothalamus of a single urethan-anesthetized rat. Injections were made
in 50 nl of saline and spaced 45-75 min apart. Maximum changes in BP and HR are indicated.

FIG. 3. Changes in heart rate (HR) and blood pressure (BP) caused by microinjection of N-methyl-D-aspartic acid (NMDA; left ) and kainic acid
(KA; right ) alone or in the presence of 2-amino-5-phosphonopentanoic (AP5). AP5 was delivered in same solution as the agonists.
* Significant differences from NMDA alone (P < 0.05, by repeated ANOVA and Newman-Keuls, n = 3).

FIG. 4. Changes in heart rate and blood pressure caused by microinjection of NMDA (left) and KA (right) alone or in presence of 6-nitro- 7cyanoquinoxaline-2,3-dione (CNQX). CNQX was delivered in same solution as agonists.* Significant differences from KA alone (P < 0.05, by paired t
test, n = 3).

FIG. 5. Schematic coronal sections of rat brain adapted from Konig and Klippel (14). Effects on heart rate elicited by microinjections of 6.8pmol
N-methyl-D-aspartic acid at each of 19 sites in 11 rats. Open circles: heart rate (HR) increased by <25 beats/min. Half-filled circles: HR increased by 2549 beats/min. Filled circles: HR increased by ≥50 beats/min. DM, dorsomedial nucleus of the hypothalamus; DP, dorsal premammillary nucleus; F,
fornix; LH, lateral hypothalamic area; MT, mammillothalamic tract; PH, posterior hypothalamus; RE, reuniens nucleus of the thalamus; VM,
ventromedial hypothalamus; ZI, zona incerta; 3V, third ventricle.

FIG. 6. Photomicrograph of injection site in dorsomedial hypothalamus at which 6.8pmol N-methyl-D-aspartic acid increased heart rate by 59
beats/min. Site was marked with 50 nl of india ink that was diluted 1:1 with saline. Bar, 1 mm. Schematic coronal sections of rat brain at comparable
levels adapted from atlases of Pellegrino et al. (A) and Konig and Klippel (B). Abbreviations same as defined in Fig. 5 legend.

